Researchers Coax Secrets, Possible Drug Targets From Multiple Myeloma Genome
This article was originally published in The Pink Sheet Daily
Executive Summary
The whole genome study suggests new targets for the incurable bone-marrow cancer, but even the nearest at hand could be years away from producing a therapeutic agent.
You may also be interested in...
Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout
Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.
Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma
As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.
Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials
Bolstered by a huge patient database, the Multiple Myeloma Research Consortium is helping to speed trials of new therapies, including some of the most talked about investigational drugs in the disease space, like carfilzomib and pomalidomide.